看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 5.9x - 6.5x | 6.2x |
| Selected Fwd Ps Multiple | 4.0x - 4.4x | 4.2x |
| Fair Value | $21.82 - $24.12 | $22.97 |
| Upside | -10.1% - -0.6% | -5.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | PINC:TRVN |
| Catalyst Pharmaceuticals, Inc. | - | NasdaqCM:CPRX |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | CPRX | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | PINC:TRVN | NasdaqCM:CPRX | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 15.8% | NM- | 22.8% | 178.4% | -11.4% | 36.9% | ||
| 3Y CAGR | 13.3% | NM- | 23.9% | 280.9% | 0.6% | 51.7% | ||
| Latest Twelve Months | 20.6% | NM | 40.0% | 32386.9% | -83.0% | 23.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -404.2% | -19098.5% | -7594.3% | -23982.0% | -19680.3% | 35.8% | ||
| Prior Fiscal Year | -234.4% | NA | -8496.9% | -77690.7% | 12839.7% | 17.9% | ||
| Latest Fiscal Year | -166.2% | -63986.5% | -6655.2% | -226.7% | -1289.2% | 33.3% | ||
| Latest Twelve Months | -166.2% | -2758.7% | -6655.2% | -226.7% | -6233.7% | 33.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | NA | -1.3x | -2.1x | -3.2x | -0.8x | 10.8x | ||
| Price / LTM Sales | 10.3x | 0.3x | 277.1x | 12.0x | 2.0x | 6.2x | ||
| LTM P/E Ratio | -6.2x | 0.0x | -4.2x | -5.3x | 0.0x | 18.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 10.3x | 277.1x | |||||
| Historical LTM P/S Ratio | 2.9x | 5.2x | 10.1x | |||||
| Selected Price / Sales Multiple | 5.9x | 6.2x | 6.5x | |||||
| (x) LTM Sales | 492 | 492 | 492 | |||||
| (=) Equity Value | 2,896 | 3,048 | 3,201 | |||||
| (/) Shares Outstanding | 122.0 | 122.0 | 122.0 | |||||
| Implied Value Range | 23.74 | 24.99 | 26.24 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 23.74 | 24.99 | 26.24 | 24.27 | ||||
| Upside / (Downside) | -2.2% | 3.0% | 8.1% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | CPRX | |
| Value of Common Equity | 36 | 1 | 180 | 911 | 1 | 2,960 | |
| (/) Shares Outstanding | 30.1 | 8.3 | 66.5 | 636.9 | 0.9 | 122.0 | |
| Implied Stock Price | 1.21 | 0.08 | 2.71 | 1.43 | 1.28 | 24.27 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1.21 | 0.08 | 2.71 | 1.43 | 1.28 | 24.27 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |